Website Links
Description
Greffex’s innovation in preventing immune rejection has been built upon the company’s proprietary fully deleted, helper virus-independent adenoviral vector, which will soon be implemented therapeutically for hepatocyte and kidney transplantation. Greffex and UPMC/ISMETT have agreed to jointly investigate Greffex's approach to immune suppression at ISMETT, one of the world’s foremost transplantation centers. A fully integrated biopharmaceutical company, Greffex, Incorporated was founded to develop therapies for previously untreatable diseases and conditions. Greffex’s scientists have since advanced therapies across multiple disease platforms, overcoming immune interference in regenerative treatments such as gene and transplantation therapy. Greffex created and patented the only fully deleted, helper virus-independent adenoviral vector capable of mitigating immune risks inherent in early-generation adenoviral vectors. This innovation also overcomes previous viral vector technologies’ limitations, such as reduced therapeutic efficacy, limited transgene capacity, intrinsic viral toxicity and inferior production efficiency. Greffex’s second set of patented technologies, Engineered Veto